Frequency of centromeric and telomeric KIR haplotypes in UC, CD, and control subjects.

<p>Frequency of centromeric and telomeric KIR haplotypes in UC, CD, and control subjects.</p

Frequency of each KIR gene in 90 patients with UC, 50 patients with CD, and 325 healthy subjects.

<p>Frequency of each KIR gene in 90 patients with UC, 50 patients with CD, and 325 healthy subjects.</p

Frequency of KIR-HLA combinations in UC, CD, and control subjects.

<p>Frequency of KIR-HLA combinations in UC, CD, and control subjects.</p

Associations of HLA-Bw4, HLA-C1, and HLA-C2 ligands with KIR in UC, CD, and control subjects.

<p>Associations of HLA-Bw4, HLA-C1, and HLA-C2 ligands with KIR in UC, CD, and control subjects.</p

Demographic and Clinical Characteristics of 156 Patients with Type 1 AIH.

<p>Values are expressed as median (range) unless otherwise noted.</p><p>Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ANA, anti-nuclear antibody; SMA, anti-smooth muscle antibody.</p

Influence of Three Amino Acid Positions in HLA-DRβ1 Associated with AIH Risk or Protection.

<p>Abbreviations: HLA, human leukocyte antigen; AIH, autoimmune hepatitis; OR, odds ratio; CI, confidence interval.</p

Statistical Analysis of Representative HLA Alleles among Patients with Type 1 AIH and Healthy Subjects.

<p>Abbreviations: Pc, corrected P; OR, odds ratio; CI, confidence interval.</p

Relative amino acid positions at β11, β13, and β57 on the HLA-DRB1 molecule.

<p>Three-dimensional structure of HLA-DRB1 adapted from Stern et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100565#pone.0100565-Stern1" target="_blank">[40]</a> The molecule is composed of 2 opposing α-helices and a series of supporting β-pleated sheets. The relative positions of the 3 amino acids discussed in this study are indicated by black spots.</p

Number of Individuals with Haplotypes Containing HLA-DRB1*04:05-DQB1*04:01.

<p>x represents any allele at that locus, including A*24:02, C*01:02, B*54:01, and DPB1*05:01.</p

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C - Fig 6

<p><b>Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 9 female patients without a SVR.</b> PT: post-treatment. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01.</p